BRIEF-Adjuvant Libtayo® (Cemiplimab) Significantly Improves Disease-Free Survival After Surgery In High-Risk Cutaneous Squamous Cell Carcinoma In Phase 3 Trial
ReutersJan 13, 2025 11:26 AM
Jan 13 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
ADJUVANT LIBTAYO® (CEMIPLIMAB) SIGNIFICANTLY IMPROVES DISEASE-FREE SURVIVAL (DFS) AFTER SURGERY IN HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) IN PHASE 3 TRIAL
LIBTAYO SHOWS SIGNIFICANT BENEFIT IN HIGH-RISK CSCC ADJUVANT SETTING
PRIMARY ENDPOINT OF DFS MET WITH 68% RISK REDUCTION IN HIGH-RISK CSCC
Source text: ID:nGNX2KKH7N
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
What Are Meme Coins? From DOGE to SHIB, PEPE to PENGU — The Hype, the Culture, and the Risk
Meme coins are cryptocurrencies inspired by internet culture — often humorous, ironic, or satirical in nature. Unlike Bitcoin (BTC) or Ethereum (ETH), which aim to solve technical or financial problems, meme coins thrive on community hype, viral storytelling, and low entry barriers.TradingKey
6 hours ago
Investing in Robotics Stocks
TradingKey - Robotics has graduated from being a specialized technical innovation to one of the most powerful enablers of productivity in today's economy. Robots are no longer restricted to auto plants and lab coats and now operate across sectors, healthcare and agriculture as well as logistics...TradingKey
7 hours ago
AMD Q2 FY2025 Earnings Review: Impressive Growth Stumbles on Export Control Hurdles
TradingKey - Advanced Micro Devices, Inc. (NASDAQ: AMD) released its Q2 FY2025 earnings on August 5, 2025, after market close, delivering robust results driven by record sales in its Data Center and Client segments. Despite a 32% YoY revenue increase, surpassing expectations, the stock dipped aroundTradingKey
11 hours ago
